Founded in 1978 as the National Neurofibromatosis Foundation, the Children's Tumor Foundation (CTF) is a nonprofit organization committed to identifying effective drug therapies for neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis, as well as improving the lives of those living with these disorders.
NF causes a range of brain and nerve tumors (benign and malignant), bone abnormalities, learning disabilities, pain, vascular complications, and other manifestations. The progress of NF is unpredictable and often presents a chronic lifelong burden to the affected person. The signaling pathways affected in NF are common to many other tumor disorders and many existing drugs developed for these disorders could be effective in NF.
To that end, CTF and scientific journal PLOS ONE are inviting applications for the Drug Discovery Initiative Registered Report (DDI-RR) Awards. Launched in 2017, the DDI-RR places particular emphasis on transparency in the research and peer review process. This format is designed to minimize publication bias and several forms of research bias while also allowing complete flexibility to conduct exploratory (unregistered) analyses and report serendipitous findings. Registered Reports represent a major departure from the standard research and peer review process and are set to revamp the publishing landscape.
The awards program will support early-stage testing of candidate drug therapies for the treatment of neurofibromatosis (NF): NF1, NF2, and schwannomatosis. Through the program, grants of up to $40,000 will be awarded in support of cell-based preclinical drug testing studies, whil grants of up to $85,000 will be awarded in support of animal-based preclinical drug testing studies.
To be eligible, applicants must have an MD, PhD, or equivalent and have full access (or identified collaborators with full access) to all required resources, including all in vivo and in vitro models. There is no citizenship requirement.
See the Children's Tumor Foundation website for complete program guidelines and application instructions.